A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
Public ClinicalTrials.gov record NCT02246621. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer With No Prior Systemic Therapy in This Disease Setting
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to evaluate how effective nonsteroidal aromatase inhibitors (NSAI) plus abemaciclib are in postmenopausal women with breast cancer. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio.
Study identification
- NCT ID
- NCT02246621
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 493 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 6, 2014 (Actual)
- Primary completion
- Jan 31, 2017 (Actual)
- Completion
- Dec 2026 (Estimated)
- Last update posted
- Feb 3, 2026
2014 – 2026
United States locations
- U.S. sites
- 20
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ironwood Cancer & Research Centers | Chandler | Arizona | 85224 | — |
| Highlands Oncology Group | Springdale | Arkansas | 72762 | — |
| CBCC Global Research, Inc. | Bakersfield | California | 93309 | — |
| California Cancer Associates Research and Excellence | Fresno | California | 93720 | — |
| TRIO-US (Translational Research in Oncology-US) | Los Angeles | California | 90024 | — |
| Central Coast Medical Oncology Corporation | Los Angeles | California | 90095 | — |
| Orlando Health, Inc | Los Angeles | California | 90095 | — |
| North Valley Hematology/Oncology Medical Group | Los Angeles | California | 95817 | — |
| UCLA Hematology/Oncology - Parkside | Santa Monica | California | 90404 | — |
| Holy Cross Hospital | Fort Lauderdale | Florida | 33308 | — |
| Lakes Research, LLC | Miami Lakes | Florida | 33104 | — |
| Candler Medical Oncology Practice - Statesboro | Savannah | Georgia | 31404 | — |
| Candler Medical Oncology Practice - Statesboro | Savannah | Georgia | 31405 | — |
| Mayo Clinic in Rochester, Minnesota | Rochester | Minnesota | 55905 | — |
| Nebraska Hematology-Oncology, P.C. | Lincoln | Nebraska | 68506 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| Mount Sinai Cancer Center | New York | New York | 10011 | — |
| University of Tennessee Medical Center | Knoxville | Tennessee | 37920 | — |
| Oncology Consultants P.A. | Houston | Texas | 77030 | — |
| Joe Arrington Cancer Center | Lubbock | Texas | 79410 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 135 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02246621, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 3, 2026 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02246621 live on ClinicalTrials.gov.